Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 19,275 $ 45,006
Short-term investments 171,227 166,864
Accounts receivable, net 36,003 30,424
Inventory 25,392 13,294
Income taxes receivable 0 4,614
Other current assets 2,097 3,399
Total current assets 253,994 263,601
Deferred income taxes, net 8,530 8,530
Intangible assets, net 314,843 342,455
Goodwill 103,770 105,673
Commercial license rights, net 6,602 10,182
Property and equipment, net 16,178 12,482
Operating lease right-of-use assets 6,235 10,914
Financing lease right-of-use assets 3,566 4,095
Equity method investment in Primrose Bio 13,985 0
Equity securities in Primrose Bio 33,097 0
Other assets 8,426 4,736
Total assets 769,226 762,668
Current liabilities:    
Accounts payable 2,475 5,307
Accrued liabilities 10,635 15,681
Income taxes payable 1,204 0
Current operating lease liabilities 497 670
2023 convertible senior notes, net 0 76,695
Other current liabilities 916 457
Total current liabilities 15,727 98,810
Long-term contingent liabilities 3,515 3,456
Deferred income taxes, net 32,586 30,615
Long-term operating lease liabilities 5,832 10,336
Other long-term liabilities 43,670 21,966
Total liabilities 101,330 165,183
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at September 30, 2023 and December 31, 2022 0 0
Common stock, $0.001 par value; 60,000 shares authorized; 17,421 and 16,951 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively 18 17
Additional paid-in capital 183,994 147,590
Accumulated other comprehensive loss (944) (984)
Retained earnings 484,828 450,862
Total stockholders' equity 667,896 597,485
Total liabilities and stockholders' equity $ 769,226 $ 762,668